ライフサイエンスコーパス: CRISPR

1 CRISPR is a versatile gene editing tool which has revolu

2 CRISPR saturation mutagenesis has the potential to disse

3 CRISPR technology, however, presents the opposite dilemm

4 CRISPR-Cas are prokaryotic adaptive immune systems that

5 CRISPR-Cas systems allow bacteria and archaea to acquire

6 CRISPR-Cas systems are efficient and easily programmable

7 CRISPR-Cas systems depend on the Cas1-Cas2 integrase to

8 CRISPR-Cas systems have potential for many microbial eng

9 CRISPR-Cas systems provide microbes with adaptive immuni

10 CRISPR-Cas systems provide prokaryotes with adaptive def

11 CRISPR-Cas9 can be applied to correct disease-causing ge

12 CRISPR-Cas9 gene editing revealed that both BTK and B ly

13 CRISPR-Cas9 has become a facile genome editing technolog

14 CRISPR-Cas9 is a genome editing technology with major im

15 CRISPR/Cas is a revolutionary gene editing technology wi

16 CRISPR/Cas9 genome editing generated predicted null muta

17 CRISPR/Cas9 genomics revealed that super-enhancer consti

18 CRISPR/Cas9 holds immense potential to treat a range of

19 CRISPR/Cas9 induced high rates (88-100%) of mutagenesis

20 CRISPR/Cas9 is a promising tool for genome-editing DNA i

21 CRISPR/CAS9 knockout of YAP in hESCs enables Activin to

22 CRISPR/Cas9 was developed such that targeted genomic les

23 CRISPR/Cas9 was used to delete defined rhomboid enhancer

24 CRISPR/Cas9-based genome editing can easily generate kno

25 CRISPR/Cas9-based genome editing offers the possibility

26 CRISPR/Cas9-mediated deletion or silencing of MANTIS wit

27 ce proteins to block the function of class 1 CRISPR-Cas systems.

28 ndromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system is emerging as a robust biotechnolog

29 A CRISPR/Cas9-based screen of PAX5 and IKZF1 transcription

30 tions to this issue, we design and analyse a CRISPR-Cas9 library with 10 variable-length guides per g

31 d the binding specificity was validated by a CRISPR/Cas9 mediated ZnT8 knock-out.

32 a GCD2 patient was corrected by delivering a CRISPR plasmid expressing Cas9/gRNA and a single-strande

33 Here, we describe a CRISPR affinity purification in situ of regulatory eleme

34 Here, we describe a CRISPR-based system that uses pairs of guide RNAs (gRNAs

35 We developed a CRISPR interference (CRISPRi) platform targeting 16,401

36 Here, we developed a CRISPR-Cas9-based 'gene drive array' platform to facilit

37 with isothermal amplification to establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA

38 In type I-E and II-A CRISPR-Cas systems, this adaptation process is driven by

39 ed to the discovery of four unique type II-A CRISPR-Cas9 inhibitor proteins encoded by Listeria monoc

40 tion and establish a link between Type III-A CRISPR-Cas immunity and central nucleic acid metabolism.

41 Here we estimate the number of spacers in a CRISPR array of a prokaryotic cell which maximizes its p

42 ched in cell-essential genes identified in a CRISPR screen, as well as in genes with reported roles i

43 bacterial genomes for the co-existence of a CRISPR spacer and its target, a potential indicator for

44 To investigate this question, we use a CRISPR-dCas9 epigenetic editing tool, where an inactive

45 TF7IP and PDE4B genes, respectively, using a CRISPR-Cas9 approach.

46 In type VI-A CRISPR-Cas systems, the signature protein Cas13a (former

47 From a single transformation with a CRISPR library targeting the immunity-associated leucine

48 ment, in concert with a mitochondria-adapted CRISPR/Cas9 platform, could prompt a revolution in mitoc

49 Although CRISPR/Cas9 has been extensively used to manipulate the

50 R interference mechanism varies widely among CRISPR-Cas systems, the spacer integration mechanism is

51 20291 shows allelic regulatory activity, and CRISPR/Cas9 targeting of human chondrocytes demonstrates

52 Cas-proteins that cleave the foreign DNA and CRISPR array that suits as a virus recognition key.

53 more sensitive to MAP kinase inhibition, and CRISPR-Cas9-mediated replacement of WT KRAS with a mutan

54 d zinc finger transcriptional repressors and CRISPR-Cas9 methods aiming to reduce transcription by ta

55 ile on a subset of genes, including rRNA and CRISPR loci, Spt4/5 is recruited to the transcription el

56 of unknown function, have been ascribed anti-CRISPR function.

57 Small bacteriophage-encoded anti-CRISPR proteins (Acrs) can inactivate Cas9, providing an

58 These natural Cas9-specific "anti-CRISPRs" present tools that can be used to regulate the

59 Here we applied CRISPR-Cas9 genome editing to disrupt the endogenous hum

60 Here we apply CRISPR-Cas9 gene editing to tag a cytoskeletal protein (

61 nd mosaicism are major concerns for applying CRISPR-Cas9 to correct genetic mutations.

62 ct a genome-wide, sequence-verified, arrayed CRISPR library.

63 Bacterial CRISPR-Cas systems comprise diverse effector endonucleas

64 The bacterial CRISPR-Cas9 immune system has been harnessed as a powerf

65 ing pathways was confirmed in human cells by CRISPR/Cas9-mediated gene inactivation.

66 n which the V247fs mutation was corrected by CRISPR/Cas9-based genome editing (V247fs-MT-correction).

67 hat the location of specific sites on DNA by CRISPR Cas9 proteins is governed by binding first to pro

68 s of current knowledge of genomic editing by CRISPR/Cas9 technology as a feasible strategy for global

69 pidermal progenitors that were engineered by CRISPR-mediated genome editing to controllably release G

70 Loss of CXCR7 expression by CRISPR-Cas9 gene editing resulted in a halt of cell prol

71 equent consequence of mutations generated by CRISPR/Cas9 gene-editing technology, and alleles designe

72 GATA4 was interrupted by CRISPR-Cas9 in induced pluripotent stem cells from healt

73 Axonal transport defects are rescued by CRISPR/Cas9-mediated genetic correction of the FUS mutat

74 ntified with HiChIP are further supported by CRISPR interference and activation at linked enhancers,

75 omoter::GU-US reporter transgene targeted by CRISPR/Cas9.

76 Moreover, lethal self-targeting by CRISPR systems may contribute to host genome stability b

77 tive crRNAs are expressed, self-targeting by CRISPR-Cas causes no reduction in transformation efficie

78 eatures could be evaluated by characterizing CRISPR-induced allelic variation in the conserved kinase

79 pproaches and allows for generation of clean CRISPR/Cas9-based KOs.

80 Here we combine CRISPR/Cas9 gene editing with an innovative high-through

81 as enabled biomedical researchers to conduct CRISPR-based genetic screens in a pooled format.

82 we describe a molecular device that couples CRISPR-dCas9 genome regulation to diverse natural and sy

83 nterspaced short palindromic repeat (CRISPR)-CRISPR-associated (Cas) systems detect and degrade invas

84 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated editing in 2

85 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 (Cas9) technology, simultane

86 However, current CRISPR-Cas technologies are based solely on systems from

87 leukemia (AML) human cell lines and a custom CRISPR/Cas9 screening platform, we identify the H3K9 met

88 s for individual labs to generate customized CRISPR libraries of variable size and coverage depth for

89 sfection was further demonstrated to deliver CRISPR-Cas9 systems to successfully modify and reprogram

90 Here, we deploy CRISPR/Cas9 technology to demonstrate a variety of sophi

91 e Picker serves as a meta tool for designing CRISPR experiments by presenting ten different guide RNA

92 nition, opening new opportunities to develop CRISPR-based tools with enhanced targeting capabilities.

93 tion to establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA or RNA detection with at

94 Here, we employ diverse CRISPR/Cas9 genome editing tools to generate a series of

95 ur results highlight the role of Cas9 during CRISPR immunization and provide a useful tool to study t

96 Easi-CRISPR solves the major problem of animal genome enginee

97 New single-component effector CRISPR systems are emerging from the bioinformatics pipe

98 Here the authors employ CRISPR/Cas9 gene editing technology to silence VEGFR2, a

99 Here we employ CRISPR/Cas9 to facilitate use of the dimerisable Cre-rec

100 The majority of archaea encode CRISPR-Cas systems but only a few CRISPR-Cas-based genet

101 The RNA-guided endonuclease CRISPR-associated protein 9 (Cas9), in particular, has a

102 Our results establish CRISPR-Cas13a as a flexible platform for studying RNA in

103 To establish CRISPR-directed gene editing in N. vitripennis, we targe

104 The type I-F CRISPR adaptive immune system in Pseudomonas aeruginosa

105 n7-like transposons contain minimal type I-F CRISPR-Cas systems that consist of fused cas8f and cas5f

106 We called these elements false-CRISPRs and further classified them into groups, includi

107 aea encode CRISPR-Cas systems but only a few CRISPR-Cas-based genetic tools have been developed for o

108 omic repeat (CRISPR) loci and their flanking CRISPR-associated (cas) genes make up RNA-guided, adapti

109 er and its target, a potential indicator for CRISPR inhibition.

110 s9), which expands the temperature range for CRISPR-Cas9 applications.

111 diRNAs were not detected from CRISPR/Cas9- or TALEN-induced DSBs within the examined e

112 thod to estimate gene-dependency levels from CRISPR-Cas9 essentiality screens while accounting for th

113 w study employs genome-wide loss-of-function CRISPR/Cas9 screening to identify three novel factors fo

114 It was previously observed that functional CRISPR-Cas systems are absent from multidrug-resistant (

115 Palindromic Repeats/CRISPR-associated gene9 (CRISPR/Cas9) gene editing technology.

116 Whereas the RNA-guided CRISPR interference mechanism varies widely among CRISPR

117 RNA-guided CRISPR-Cas9 endonucleases are widely used for genome eng

118 er single-positive, non-target NCI-H358-HER2 CRISPR knock out tumors in nude mice bearing dual-flank

119 l obstacles that will need to be overcome if CRISPR-Cas9 is to be used in the practice of cardiovascu

120 For type I and II CRISPR-Cas systems, single-nucleotide mutations in the s

121 hylococcus aureus cells harbouring a type II CRISPR-Cas9 system after infection with the staphylococc

122 systems, the relaxed specificity of type III CRISPR-Cas targeting provides robust immune responses th

123 Here we implement CRISPR-Cas9 genome editing and transposon-mediated somat

124 functional alleles and normal phenotypes in CRISPR-edited mutants.

125 The revolution in CRISPR-mediated genome editing has enabled the mutation

126 t phenotype by several approaches, including CRISPR-mediated inactivation of FGFR3-TACC3 fusion genes

127 cible control; and circuits that incorporate CRISPR-Cas9 to regulate endogenous genes.

128 ns, we generated and characterized inducible CRISPR/Cas9 knockout human cell lines targeting 209 gene

129 ribe the generation of transgenic, inducible CRISPR-based mouse systems to engineer and study recurre

130 Hence, an initial CRISPR/Cas9-mediated genetic modification approach has i

131 agments and channels them for insertion into CRISPR array.

132 osterically activates Csm6 by binding to its CRISPR-associated Rossmann fold (CARF) domain.

133 which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delivery to postmitotic photoreceptors is us

134 of genomic VEGFR2 locus using rAAV1-mediated CRISPR/Cas9 abrogates angiogenesis in the mouse models o

135 -guided endonuclease Cas9 from the microbial CRISPR (clustered regularly interspaced short palindromi

136 Moreover, CRISPR-Cas9-mediated deletion of candidate enhancers/SEs

137 hoice of approach (for example, mutagenesis, CRISPR-based gene editing, RNA interference, morpholinos

138 ity, and fundamental capabilities of natural CRISPR systems, and we highlight some of the remarkable

139 We used the double-nicking CRISPR/Cas9 system to conduct site-specific mutagenesis

140 We describe novel CRISPR/Cas9 transfection plasmids and approaches for the

141 Now, CRISPR-Cas9 tools for site-specific genome editing are n

142 ic repeats and the Cas9 RNA-guided nuclease (CRISPR/Cas9) system provides a new opportunity to create

143 that the efficiency of protective action of CRISPR-Cas systems against different viruses should vary

144 egulate the genome engineering activities of CRISPR-Cas9.

145 Adaptation of CRISPR-Cas9 for genome-editing applications has revoluti

146 The rapid adoption of CRISPR technology has enabled biomedical researchers to

147 the powerful multiplex targeting capacity of CRISPR/Cas9.

148 e explore the fundamental characteristics of CRISPR-Cas systems and highlight how these features can

149 ere we report that single-step codelivery of CRISPR/Cpf1 ribonucleoproteins with single-stranded DNA

150 The key components of CRISPR/Cas9 are guide RNAs (gRNAs) which determine speci

151 we interrogate the molecular consequences of CRISPR/Cas9-mediated deletions at 17 sites in four loci

152 We propose that in the course of CRISPR interference Cas3 generates fragments of foreign

153 The safe, non-viral delivery of CRISPR/Cas components would greatly improve future thera

154 iding a basis for the further engineering of CRISPR-Cpf1.

155 To evaluate the feasibility of CRISPR/Cas9-based cardiac genome editing in vivo in post

156 Recently, the RNA-guidable feature of CRISPR-Cas9 has been utilized for imaging of chromatin w

157 identification of the biological function of CRISPR-Cas as adaptive immune systems in bacteria.

158 RNA (sgRNA), which abrogates the function of CRISPR-transcriptional activators.

159 Successful implementation of CRISPR often requires Cas9 to elicit efficient target kn

160 We find that forced maintenance of CRISPR targets induces a fitness cost that can be exploi

161 s-disabled sheep by oocyte microinjection of CRISPR/Cas9 targeting PDX1, a critical gene for pancreas

162 ntifying genome-wide off-target mutations of CRISPR-Cas9.

163 solved metagenomics, we identify a number of CRISPR-Cas systems, including the first reported Cas9 in

164 The gene editing potential of CRISPR/Cas9 encapsulated by ZIF-8 (CC-ZIFs) is further v

165 mmunobiology and underscore the potential of CRISPR/Cas9 genome editing to advance immunotherapies.

166 in vivo and expands the temperature range of CRISPR-Cas9.

167 undergone targeted mutations as a result of CRISPR/Cas9 activity.

168 ls based on the continually expanding set of CRISPR-Cas systems.

169 leavage is critical to ensure the success of CRISPR screens.

170 This toolkit of CRISPR-coupled GPCRs provides a modular platform for rew

171 We demonstrate the use of CRISPR-Cas9 to edit an endogenous insect cell gene and a

172 osomal dominant disease to assess the use of CRISPR/Cas9 in two allele-specific systems, comparing cl

173 A major concern for the use of CRISPR/Cas9 is its tendency to cleave DNA non-specifical

174 However, the practical therapeutic use of CRISPR/Cas9 is still questionable due to current shortco

175 The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous trans

176 es are required to expand the versatility of CRISPR/Cas9 as a robust tool to study novel cardiac gene

177 blastocyst complementation platform based on CRISPR-Cas9-mediated zygote genome editing and show enri

178 etformin, inhibition of mTORC by torin 1, or CRISPR/Cas9-mediated genetic knock-out of tuberous scler

179 ber of genomes have isolated cas loci and/or CRISPRs.

180 occus faecalis, which only possess an orphan CRISPR locus, termed CRISPR2, lacking cas genes.

181 editing outcomes, and compare them to other CRISPR genome-editing technologies.

182 anipulations, including gene overexpression, CRISPR/Cas9 gene editing, inducible technologies, optoge

183 Pooled CRISPR-Cas9 knock out screens provide a valuable additio

184 By transforming pooled CRISPR libraries into tomato (Solanum lycopersicum), col

185 esults indicate that the effect of postnatal CRISPR/Cas9-based cardiac gene editing using adeno-assoc

186 n human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-d

187 Here we present CRISPR-UMI, a single-cell lineage-tracing methodology fo

188 e describe the development of a programmable CRISPR system capable of specifically visualizing and el

189 namic and secondary structure models on real CRISPR datasets.

190 ularly interspaced short palindromic repeat (CRISPR) loci and their flanking CRISPR-associated (cas)

191 ularly interspaced short palindromic repeat (CRISPR)-Cas9 system and measured the quantities of bindi

192 ularly interspaced short palindromic repeat (CRISPR)-Cas9 technology, gene-specific small interfering

193 ularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated (Cas) systems detect and degra

194 larly interspaced short palindromic repeats (CRISPR)-associated proteins (Cas) that utilize RNA to fi

195 larly interspaced short palindromic repeats (CRISPR)-Cas9 platform for in situ high-content functiona

196 larly interspaced short palindromic repeats (CRISPR)-enzymatically inactive Cas9 in MVM-infected cell

197 larly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated edit

198 larly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 (Cas9) technology, s

199 larly interspaced short palindromic repeats (CRISPR-Cas9)-mediated gene editing.

200 ularly Interspaced Short Palindromic Repeats/CRISPR-associated gene9 (CRISPR/Cas9) gene editing techn

201 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system is emer

202 ed regularly interspaced palindromic repeats/CRISPR-associated) homology-directed repair gene-editing

203 Gang et al. report CRISPR/Cas9 genome editing in parasites of the genus Str

204 expected to provide an efficacious and safe CRISPR/Cas9 antimicrobial, broadly applicable to Staphyl

205 er dependency map, we performed genome-scale CRISPR-Cas9 essentiality screens across 342 cancer cell

206 Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma an

207 host genome (self) sequences into its seven CRISPR loci.

208 nd cas5f, cas7f, and cas6f genes and a short CRISPR array.

209 referentially interacts with the leader-side CRISPR repeat, and finally, it catalyses a nucleophilic

210 a (PA14) consists of two CRISPR loci and six CRISPR-associated (cas) genes.

211 ive method to construct multiple small sized CRISPR library from a single oligo pool generated by arr

212 In challenging a S. thermophilus strain CRISPR-immunized against a set of virulent phages, we fo

213 In this study, CRISPR/Cas9 was utilized to successfully target the chan

214 spacer acquisition that ensures a successful CRISPR immune response.

215 Here, by systematic CRISPR/Cas9-assisted deletions of chromatin accessible r

216 As demonstrated here, targeted CRISPR disruption is a valuable tool for functional stud

217 Using gene editing technology (CRISPR/Cas9), the SIRT1 gene was removed from cervical c

218 We demonstrate that CRISPR-Cas activity and acquisition of resistance can be

219 These data demonstrate that CRISPR-Cas9 can be used to generate multiple subtypes of

220 Here, we demonstrate that CRISPR/Cas9 genome editing of promoters generates divers

221 discusses the unprecedented opportunity that CRISPR/Cas9 technology offers for investigating and mani

222 Our results reveal that CRISPR-Cas systems exploit the phage life cycle to gener

223 Our data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a pro

224 The CRISPR (clustered regularly interspaced short palindromi

225 The CRISPR and the cas locus are often located next to each

226 The CRISPR-Cas systems in prokaryotes are RNA-guided immune

227 The CRISPR-Cas9 genome-editing system is a part of the adapt

228 The CRISPR/Ca9s system is also being used for high-throughpu

229 The CRISPR/Cas System has been shown to be an efficient and

230 The CRISPR/Cas9 complex, a bacterial immune response system,

231 As, including miRNAs, can be targeted by the CRISPR/Cas9 system despite their lacking an open reading

232 ITPR2-knockout HepG2 cells generated by the CRISPR/Cas9 system.

233 irulent phages, we found one that evaded the CRISPR-encoded immunity >40,000x more often than the oth

234 Mathematical modeling suggests that for the CRISPR ChaCha design, multiple dCas9 molecules can be re

235 osion in development of applications for the CRISPR-Cas9 system, from efficient genome editing, to hi

236 tegrate short foreign DNA fragments into the CRISPR locus, enabling adaptation to new viruses.

237 variety of spacers dilutes the number of the CRISPR complexes armed with the most recent and thus mos

238 We also uncover underlying principles of the CRISPR-Cas adaptation system, including sequence determi

239 ge is the safe and efficient delivery of the CRISPR-Cas9 genome-editing system to target cells in hum

240 improve our mechanistic understanding of the CRISPR-Cas9 systems and may facilitate Cas9 engineering.

241 In conclusion, applications of the CRISPR/Cas system are expanding at a breath-taking pace

242 We show that the CRISPR-STOP method is an efficient and less deleterious

243 Here we use the CRISPR-Cas system to encode the pixel values of black an

244 different strategies to edit genes using the CRISPR-Cas9 system.

245 rom NOD/SCID/IL2rg(-/-) (NSI) mice using the CRISPR/Cas9 system.

246 the powdery mildew fungal pathogen using the CRISPR/Cas9 technology.

247 cent proof of principle experiments with the CRISPR-Cas9 system as a drive mechanism.

248 acks chromosomal loci in live cells with the CRISPR-Cas9 system, then barcodes those loci by DNA sequ

249 ies to optimize knockout efficiency with the CRISPR/Cas9 system.

250 Together, these CRISPR-generated models represent a new and simple tool

251 Through CRISPR/Cas9-mediated deletions, we demonstrate a physiol

252 tial for regulating ALAS2 expression through CRISPR/Cas9-mediated site-specific deletion.

253 Thus, CRISPR-Trap offers several advantages over conventional

254 seudomonas aeruginosa (PA14) consists of two CRISPR loci and six CRISPR-associated (cas) genes.

255 onal impact of these genes using an unbiased CRISPR screen of DLBCL cell lines to define oncogenes th

256 Here, we use CRISPR base editors to knock out genes by changing singl

257 Here we use CRISPR-Cas9 screening strategies in two distinct human c

258 Here we use CRISPR-Cas9-mediated genome editing to investigate the f

259 Towards this end, we used CRISPR-Cas9 genome editing to make a single allele knock

260 We used CRISPR-Cas9 technology to delete key DNA repair genes in

261 Here we used CRISPR/Cas9 genome editing to separate catalytic activit

262 We used CRISPR/Cas9 genome engineering of Drosophila legless (lg

263 Here we used CRISPR/Cas9 somatic mutagenesis to test a patterning rol

264 Here, we used CRISPR/Cas9- or TALEN-triggered DSBs to characterize diR

265 Using CRISPR-Cas9 genome editing of bptf in zebrafish to induc

266 Using CRISPR/Cas9 technology to perturb transcription factors,

267 Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologu

268 Using CRISPR/Cas9, we generated HID-1 KO rat neuroendocrine ce

269 rmination gene, transformer-2 (tra-2), using CRISPR/Cas9 (clustered regularly interspaced palindromic

270 ing their respective core biosynthesis using CRISPR interference and antibiotics, verifying our predi

271 rated SUN1(-/-) and SUN2(-/-) cells by using CRISPR/Cas9 and found that the loss of SUN1 had no effec

272 Deletion of p205 in B16 melanoma cells using CRISPR/Cas9 showed a similar loss of Asc expression.

273 andom mutations in the genomic context using CRISPR/Cas9, changed the splicing pattern.

274 n technique for precise genome editing using CRISPR-Cas9.

275 edit specific regions of the DMD gene using CRISPR/Cas9.

276 However, using CRISPR/Cas9 technology, we have shown that ACLY is not e

277 Here we model complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate that

278 d P301L:Deltap35KI isogenic iPSC lines using CRISPR/Cas9 genome editing.

279 miR-155 in FLT3-ITD(+) AML cell lines using CRISPR/Cas9, or primary FLT3-ITD(+) AML samples using lo

280 K14/23Ac of ein2-5 at the target loci, using CRISPR/dCas9-EIN2-C.

281 and efficiency of genome modifications using CRISPR.

282 sion, and genetic deletion of myomixer using CRISPR/Cas9 mutagenesis abolishes myoblast fusion in viv

283 Here the authors show, using CRISPR gene editing, ATAC-seq and ChIP-seq, that specifi

284 We utilized CRISPR/Cas9 genome editing in human induced pluripotent

285 Deletion of this locus via CRISPR-Cas9 leads to deregulation of the genes predicted

286 correction or introduction of mutations via CRISPR/Cas9 and that this iPSC-based approach can be use

287 subcellular localization of FOXO protein via CRISPR-assisted, single-stranded oligodeoxynucleotide-me

288 STR-Seq employs in vitro CRISPR-Cas9-targeted fragmentation to produce specific D

289 An in vitro CRISPR/Cas9 RNA-directed nickase system directs the spec

290 cted in cells in which endogenous Piezo1 was CRISPR/Cas9 inactivated.

291 While CRISPR/Cas9 appears to work universally, the efficiency

292 vailable second-generation human genome-wide CRISPR-KO libraries that included at least one of the im

293 With CRISPR/Cas9-mediated gene editing to stably knock out an

294 ns comparable to dSTORM can be achieved with CRISPR-PALM.

295 ly synthesized DYRK1A inhibitors, along with CRISPR-mediated gene activation and shRNA knockdown of D

296 Screening for desired clones with CRISPR-mediated genomic edits in a large number of sampl

297 Myoblast clones with CRISPR/Cas9-mediated knockout of C3G failed to show repr

298 tive gammadelta TCR used in conjunction with CRISPR/Cas9 knockout of the endogenous alphabeta TCR res

299 By using chromatin immunoprecipitation with CRISPR/Cas9 knockin of GFP fusion, we uncovered the glob

300 Here, we report that mutagenizing MELK with CRISPR/Cas9 has no effect on the fitness of basal breast